Combo Products Demand Unique Cardiac Safety Assessment – FDA Think Tank
This article was originally published in The Gray Sheet
The approval process for combination products should not be tied to the independent expectations for either drugs or devices, panelists stressed at the FDA/Duke Cardiovascular Research Institute "Cardiac Safety and the Critical Path Initiative Think Tank" Oct. 11 in Bethesda, Md
You may also be interested in...
The Heart Rhythm Society hopes to complete physician guidelines on managing device safety alerts by late spring 2006, according to the chair of the committee developing the guidelines, Mark Carlson, MD, Case Western Reserve University
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies